Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


NICE Rejects Novartis’ Xolair In Harbinger Of Cost Reevaluation Process

This article was originally published in The Pink Sheet Daily

Executive Summary

Draft guidance from NICE concludes that Novartis’ asthma drug Xolair, which was previously viewed as cost-effective, is no longer worth the expense based on new independent economic modeling and mortality data. The re-evaluation process is spreading through Europe as governments move to restrain costs, and that may spell trouble for manufacturers.


Related Content


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts